The Evolving Field of GVHD Treatment
Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.
Key Investigational Approaches for Acute and Chronic GVHD
Drs Yi-Bin Chen and Sophie Paczesny highlight data from key investigational approaches presented at recent meetings.
Treatment Options for Steroid-Refractory Chronic GVHD
Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.
The Importance of Early Treatment of Chronic GVHD
Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.
Emerging Strategies for the Treatment of Acute GVHD
Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, detail novel strategies under investigation for the treatment of acute GVHD.
Frontline Treatment Options for Acute GVHD
Experts discuss the current options for treating acute GVHD, including the use of corticosteroids and their management.
Diagnosis and Stratification of Acute and Chronic GVHD
Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.
Common Prophylaxis Regimens for GVHD
Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.
Incidence and Risk Factors of Acute and Chronic GVHD
Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.
Indications for Allogeneic Stem Cell Transplantation in the Treatment of Hematological Malignancies
Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.
Unmet Needs in GVHD Management
Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.
Supportive Care for Steroid-Refractory Chronic GVHD Treatment
Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.
Clinical Manifestations of Chronic GVHD
Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.
Future of Steroid-Refractory Chronic GVHD Treatment
Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.
Treatment Selection for Steroid-Refractory GVHD
Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.
Steroid-Refractory Chronic GVHD: Management Strategies
Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.
Steroids for First-Line Treatment of Chronic GVHD
Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.
Overview of Steroid-Refractory Acute GVHD
Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.
Evolution of Treatment for Acute GVHD
Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.
Goals of Therapy for Acute GVHD Treatment
Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.
Impact of GVHD on Patient Outcomes
Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.
ASH 2021 Updates for GVHD Prophylaxis
Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.
Selecting GVHD Prophylaxis
Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.
Challenges in Early Detection of GvHD
Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.
Overview of Graft-vs-Host Disease (GVHD)
Nelson J. Chao, MD, MBA, and Yi-Bin Chen, MD, define common signs and symptoms of GVHD and share insight on approaching the diagnosis of disease.
Final Thoughts: GVHD
All panelists provide their final thoughts on the current landscape and future directions in graft-vs-host disease (GVHD).
Steroid-Refractory Chronic GVHD
Sophie Paczesny, MD, PhD, provides an overview of the drug ibrutinib for use in steroid-refractory chronic graft-vs-host disease (GVHD). She elicits thoughts from the panelists on how they envision this drug being used.
Steroid-Refractory Acute GVHD
Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.
Steroid Refractory GVHD: Scope of the Problem
Dr Chen provides an overview of the prevalence of steroid refractory GVHD and leads a discussion on how steroid refractory GVHD is defined.
Management of Chronic GVHD
Dr Cutler leads a discussion on the approach to management of chronic GVHD and whether complete response is a realistic end point.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512